🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks Journal of Cardiac Failure HFSA for publishing our Johns Hopkins Cardiology MedStar Washington multicenter study on role of TNFalpha inhibition in #cardiacsarcoidosis treatment and effect on FDG-PET findings. Farooq Sheikh Jan Griffin @EdKasper3 Ed Chen Alison Wand onlinejcf.com/article/S1071-…

Cardiac Amyloidosis Program seeking candidates for one year post-doctoral fellowship at Columbia Medicine NewYork-Presbyterian. Training in multidisciplinary research and team based care with CUIMC depts and other centers of excellence throughout US and abroad. Columbia Cardiology Fellows

Learn everything you need to know about cardiac amyloidosis from the best mathew.maurer during a 1 yr fellowship. Jason N. Katz Ryan J Tedford MD @Brian_Houston12 Khalil Ibrahim @ersied727 @HRRosenblum Nisha Gilotra

Patients with amyloid CM in the INTERMACS registry, who received LVAD, had the highest use of BiV support and > 3-fold higher risk of death compared with DCM. Justin L. Grodin Katherine Michelis Mark Drazner mathew.maurer Nir Uriel, MD MSc @kt_heartfailure Ryan J Tedford MD @NYPCUCVI

@DrNasrien thank you for giving us a wake up call. We can do better, and we will do better #NoManels

Muthu Vaduganathan Rishi J Desai Heart_BMJ Very nice study that adds to existing literature with real world data on arni in hfref - our editorial led by Jan Griffin - heart.bmj.com/content/early/… Jan Griffin Heart_BMJ

Incredible work, Margie. Nir Uriel, MD MSc @HRRosenblum Jennifer Haythe MD Maryjane Farr MD MSc, FACC FAST FHFSA FAHA @ersied727 @NYPCUCVI

Interested in the most exciting area in Cardiology? Come join our Cardiac Amyloidosis Program at CUIMC! Opportunity to engage in cutting edge clinical research, develop an academic career and care for our amazing patients. See below to apply online. nejmcareercenter.org/job/436244/ass…

Thank you to the authors of this #amyloidosis study Martha Grogan MD, Jan Griffin, Julie Lorraine Rosenthal, Justin L. Grodin, mathew.maurer, & @RichardKCheng2. Check out the article in #JACCCardioOnc: bit.ly/3nwDNf7 5/

Thank you to my wonderful coauthors! mathew.maurer Martha Grogan MD Justin L. Grodin Julie Lorraine Rosenthal Richardkcheng

Thank you to American College of Cardiology and Michelle Kittleson MD PhD for the chance to discuss treatment of Cardiac Amyloidosis as part of this series of amazing podcasts from Michelle Kittleson MD PhD Jan Griffin and Amrut Ambardekar acc.org/Latest-in-Card…

Get the updates! Tuesday, 3/21, 9:30 AM. Only at #THT2023! ✔️Screening for ATTR-CA ✔️Insufficiency of PYP scintigraphy as a non-invasive diagnostic tool ✔️Gene therapy/CRISPR for ATTR-CA ✔️Dichotomizing ATTR-CA into neurologic and cardiac phenotypes tht2023.crfconnect.com/program-guide?…

Rates of CV hospitalizations are higher with ATTRv c/w ATTRwt CA and with increasing NTproBNP. Nice work ⁦Margie Cuomo⁩ ⁦mathew.maurer⁩ ⁦Hannia Ramos⁩ ⁦Julie Lorraine Rosenthal⁩ ⁦Kevin Alexander⁩ ⁦Jennifer Haythe MD⁩

Thanks for the invitation to speak! What a great session. Ryan J Tedford MD Rola Khedraki, MD, FACC mathew.maurer Hannia Ramos Margie Cuomo

Don’t forget to register for our virtual forum on 6/8! Cardiac speakers & panelists include Nisha Gilotra,  Chetan Shenoy, Sanjay Divakaran, Jonathan Chrispin, Jan Griffin, @JLovellMD, Jordana Kron, Farooq Sheikh, Mitchell Psotka, Mehdi Mirsaeidi, Parijat Sen, Dawn Pedrotty MD PhD! loom.ly/_W7ppm0

🔥#CharlestonHFpEFConference Alert!🔥 We have extended the deadline for research abstracts until June 11 5pm.co.uk. Travel awards for the top 2 scoring abstracts. And, abstracts will be published in the new official CardioNerds journal - #USC. Submit today! medicine.musc.edu/education/cme/…

Thank you Michael Lane for sharing your experience as a TTR amyloidosis patient at the Amyloidosis Forum Michael Lane ⁦mathew.maurer⁩ ⁦Hannia Ramos⁩ ⁦Brett Sperry, MD⁩ ⁦Mazen Hanna⁩ ⁦Amyloidosis Research Consortium⁩ ⁦U.S. FDA⁩ ⁦Martha Grogan MD⁩

Big day for patients with ATTR amyloidosis, as the topline results of ATTRIBUTE-CM are positive! Acoramidis showed significant benefit for the hierarchical composite of all-cause mortality, CV hospitalization, NTproBNP, and 6MW distance. investor.bridgebio.com/news-releases/…

📢 Fellowship Opportunity! Apply Now! 🏥 The Medical University of South Carolina’s Division of Cardiology is now accepting applications for a one-year, non-ACGME Amyloidosis Fellowship. 🔬 Gain specialized clinical & research training in amyloidosis and advance your expertise!

1/3_📢 Excited to see the results of our transatlantic registry published in #EHJ. Patients with both aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR-CA)—a group with unclear optimal management. Can AVR and tafamidis improve survival? 📄doi.org/10.1093/eurhea…